Achilles Therapeutics Pl-adr (ACHL) Technical Analysis
$1.14▲16.18%
Market is closed - opens 8 PM, 26 Dec 2024
Insights
- Achilles Therapeutics Pl-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Achilles Therapeutics Pl-adr stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Achilles Therapeutics Pl-adr stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Achilles Therapeutics Pl-adr stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 72.45 | Sell |
Stochastic | 89.9, 55.77 | Neutral |
Ultimate Oscillator | 77.14 | Sell |
Stochastic Relative Strength Index | 49.38, 29.16 | Neutral |
Moving Average Convergence Divergence | 0.0, -0.01 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.0 | Sell |
20 | 1.03 | Buy |
50 | 1.03 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.02 | Sell |
20 | 1.02 | Buy |
50 | 1.01 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.05 | Buy |
20 | 1.05 | Buy |
50 | 1.04 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.02 | Buy |
20 | 1.02 | Sell |
50 | 1.06 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.04 | Buy |
20 | 1.01 | Sell |
50 | 1.04 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 1.01 |
Resistance L2 | 1.0 |
Resistance L1 | 0.99 |
Pivot Point | 0.98 |
Support L1 | 0.97 |
Support L2 | 0.96 |
Support L3 | 0.95 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.